579 results match your criteria Chin Clin Oncol[Journal]


Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer.

Authors:
Takayuki Ueno

Chin Clin Oncol 2020 Jun;9(2):35

Breast Surgical Oncology, Breast Oncology Center, The Cancer Institute Hospital of JFCR, Tokyo, Japan.

Endocrine therapy is one of the key therapeutic components for patients with hormone receptor-positive early stage breast cancer. A lot of efforts have been made in order to explore biomarkers to select optimal endocrine treatment and optimal duration of the treatment. Estrogen receptor (ER) is the most intensively-studied and well-established biomarker for selection of endocrine treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-165DOI Listing

Clinical imaging for the prediction of neoadjuvant chemotherapy response in breast cancer.

Chin Clin Oncol 2020 Jun;9(2):31

Department of Breast and Endocrine Surgery, Kumamoto City Hospital, 4-1-60 Higashimachi, Higashi-ku, Kumamoto 862-8505, Japan.

Increased use of cancer screening, improved imaging, and diagnostic intervention techniques has led to the diagnosis of smaller cancers, including breast cancer. Most breast cancer patients receive systemic therapy, and some treatments are given before surgery, such as neoadjuvant therapy, even in an operable setting. Improved neoadjuvant chemotherapy has increased rates of pathological complete response; however, surgery is still required to determine complete tumor remission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-15DOI Listing

Local management after neoadjuvant treatment for breast cancer.

Chin Clin Oncol 2020 Jun 11;9(2):34. Epub 2020 Jun 11.

Department of Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital of JFCR, Tokyo, Japan.

Neoadjuvant chemotherapy (NAC) was originally used in patients with locally advanced breast cancer. Then, it is used in operable breast cancer to downstage the primary breast cancer and axillary lymph nodes metastasis, result in improving the cosmetic outcome and decreasing surgical morbidity. However, it is sometimes difficult to assess the extent of residual disease after NAC, as the NAC reduces the lesion and obscure the original images both breast and axilla. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-164DOI Listing

The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer.

Authors:
Masahiro Oikawa

Chin Clin Oncol 2020 Jun 12;9(2):29. Epub 2020 Jun 12.

The Department of Breast Surgery, New-wa-kai Oikawa Hospital, Fukuoka, Japan; The Department of Surgical Oncology, Nagasaki University Hospital, Nagasaki, Japan.

Chemotherapy has played a significant role in breast cancer therapy and dramatically improved the outcome of breast cancer patients. Neoadjuvant chemotherapy (NAC) is defined as chemotherapy conducted before surgery. The rationale for NAC in operable breast cancer is that the benefit of systemic chemotherapy on the long-term prognosis does not change, regardless of whether chemotherapy is conducted before or after surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-12DOI Listing

Outcomes of adjuvant whole-brain radiotherapy versus hypofractionated stereotactic radiotherapy after surgical resection of brain metastases: a propensity score-matched analysis.

Chin Clin Oncol 2020 Jun 15. Epub 2020 Jun 15.

Radiobiology laboratory, EA 3430, Federation of Translational Medicine of Strasbourg (FMTS), University of Strasbourg, Strasbourg, France.

Background: To assess the risks of local and distant failure and overall survival time in patients treated with hypofractionated stereotactic radiotherapy (HFSRT) to the postoperative cavity for brain metastases (BMs) compared with patients treated with adjuvant whole-brain radiation therapy (WBRT).

Methods: Between July 2005 and February 2015, 196 non-randomized patients with 202 resected BMs were treated with post-operative WBRT or HFSRT at a single institution. The propensity score was included as a covariate to compare the interval to local failure, distant brain failure and overall survival time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-19-269DOI Listing

The role of ramucirumab and pembrolizumab combination in patients with advanced non-small cell lung cancer, gastroesophageal adenocarcinoma, or urothelial carcinoma.

Chin Clin Oncol 2020 Jun 23. Epub 2020 Jun 23.

Department of Gastrointestinal Medical Oncology, U.T. M.D. Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-132DOI Listing

Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis.

Chin Clin Oncol 2020 Jun 16. Epub 2020 Jun 16.

Department of Surgery, Johns Hopkins Hospital, Baltimore, Maryland, USA.

Background: Radical antegrade modular pancreatosplenectomy (RAMPS) has been adopted by some surgeons in the treatment of left-sided pancreatic cancer (PDAC). Low disease incidence and heterogenous disease biology make robust prospective comparison of RAMPS and standard distal pancreatosplenectomy (DPS) difficult.

Methods: Consecutive cases of chemo-naïve patients undergoing open RAMPS and DPS for PDAC between 2010-2017 at two international high-volume pancreatectomy centers were compared. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-6DOI Listing

Efficacy and safety of radiotherapy for primary liver cancer.

Chin Clin Oncol 2020 Jun 11. Epub 2020 Jun 11.

Radiation Medicine Program, Princess Margaret Hospital, University Health Network, Toronto, Ontario, Canada; Department of Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.

Primary liver cancer includes hepatocellular carcinoma (HCC, 75-85%) and intrahepatic cholangiocarcinoma (10-15%). The vast majority of patients with primary HCC are not candidates for surgical treatment. Surgical resection, liver transplantation and percutaneous puncture are effective potentially curable treatments for patients with early stage liver cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-89DOI Listing

Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer.

Authors:
Makoto Kubo

Chin Clin Oncol 2020 Jun 8;9(2):33. Epub 2020 Jun 8.

Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Approximately 70% of women with breast cancer worldwide receive a diagnosis of ER-positive/ HER2-negative disease. Recurrence-free survival of the node-negative population of these women is approximately 85%, and most are treated with endocrine chemotherapy. Endocrine treatment for ERpositive/HER2-negative early breast cancer is a major treatment strategy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-125DOI Listing

Neoadjuvant treatment for HER2-positive breast cancer.

Chin Clin Oncol 2020 Jun 3;9(2):32. Epub 2020 Jun 3.

Department of Breast Surgery, Kyoto University Hospital, Kyoto, Japan.

Neoadjuvant therapy has become a standard clinical practice to downsize the tumor and increase the breast-conserving rate. The addition of trastuzumab to neoadjuvant chemotherapy roughly doubles the proportion of patients with HER2-positive breast cancer who achieve pathological complete response (pCR). Patients with pCR show better prognosis compared with those with residual disease after neoadjuvant therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-123DOI Listing

Hepatocellular carcinoma, novel therapies on the horizon.

Chin Clin Oncol 2020 Jun 9. Epub 2020 Jun 9.

Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Medical College at Cornell University, New York, NY, USA.

Hepatocellular carcinoma (HCC) is the most common primary liver cancer and is associated with high mortality rate. Incidence remains high due to the persistent prevalence of viral hepatitis, alcoholic cirrhosis, and non-alcoholic fatty liver disease (NFLD). Despite screening efforts, the majority of patients present with advanced disease, add to the high risk of recurrence after curative surgery. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-113DOI Listing

Imaging diagnosis of hepatocellular carcinoma: LI-RADS.

Chin Clin Oncol 2020 Jun 9. Epub 2020 Jun 9.

Liver Imaging Group, Department of Radiology, University of California San Diego, San Diego, CA 92093, USA.

Liver cancer is the third most common cause of cancer related death worldwide, 90% being hepatocellular carcinoma (HCC) and about half of all HCCs estimated to occur in China. Imaging plays a pivotal role in the management of HCC. When stringent criteria are applied to at-risk populations, it enables HCCs to be diagnosed by imaging alone without further need of invasive histology confirmation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-107DOI Listing

The optimal timing and management of hepatitis B and C in patients with hepatocellular carcinoma.

Chin Clin Oncol 2020 Jun 3. Epub 2020 Jun 3.

Division of Digestive Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer related mortality worldwide, with the most common underlying etiologies being chronic hepatitis B and hepatitis C infections. Treatment of these viral hepatidities in the setting of HCC has been debated, and there is increasing study addressing this topic. Patients with advanced HCC of either etiology are unlikely to benefit from antiviral treatments, and futility should be considered prior to starting antiviral therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-46DOI Listing

Management of glioblastoma: a perspective from Mexico.

Chin Clin Oncol 2020 May 24. Epub 2020 May 24.

Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD, USA.

Access to healthcare in Mexico is available to its population via publicly and privately funded institutions. The public sector, administered by both the local and federal government under the jurisdiction of the Department of Health, provides healthcare to the majority of the country's population. Privately funded institutions vary in size and scope of practice, ranging from small clinics focused on family practice, to large tertiary hospitals with capacity for treating patients with complex conditions and performing clinical research. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-129DOI Listing

Can lymphadenectomy be omitted in advanced ovarian cancer? A brief review.

Chin Clin Oncol 2020 Jun 3. Epub 2020 Jun 3.

Surgical Oncology, Gynecologic Tumors Division, Instituto Nacional de Cancerología, Mexico City, Mexico.

The indication of systematic lymphadenectomy in advanced ovarian cancer without apparent macroscopic lymph node involvement has been controversial over the past three decades, and the recommendation to perform it or not has been based on multiple retrospective studies, small cohort studies, and few randomized studies with several biases; however, it seems that this controversy has come to an end after the recent publication of a randomized clinical trial. The study of lymph node disease in ovarian cancer has intensified in the last two decades, so far that it was part of the changes of the last update of the International Federation of Gynecology and Obstetrics (FIGO) staging; In this review, a search was made of the available literature to understand the evolution of knowledge about the implications of the realization or not of lymphadenectomy in two scenarios of advanced ovarian cancer (namely, the presence or not of lymph node disease macroscopic), without losing the landscape of the importance of peritoneal disease in these stages, which, as we will see throughout the review, the complete cytoreduction of the tumor remains an integral part of the treatment, since residual disease is one of the most relevant prognostic factors. Nowadays, we can confidently state that systematic lymphadenectomy in patients with advanced ovarian cancer without clinically apparent nodal disease is not necessary, and the presence of macroscopic retroperitoneal lymph node disease should be resected as part of cytoreductive surgery since it will be this and the residual disease that determine the prognosis of the patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-35DOI Listing

Liver-directed therapy for hepatocellular carcinoma.

Chin Clin Oncol 2020 May 30. Epub 2020 May 30.

Department of Radiology, University of Pennsylvania, Philadelphia, PA, USA.

The high mortality rate for hepatocellular carcinoma (HCC) relative to its prevalence underscores the need for curative-intent therapies. Multidisciplinary treatment decisions are required to craft optimal treatment strategies considering tumor size, location and underlying liver cirrhosis. Surgical resection of anatomically limited tumors with adequate hepatic reserve provides long-term survival in more than half of patients and remains a standard first-line therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-51DOI Listing

Ovarian carcinoma: pathology review with an emphasis in their molecular characteristics.

Chin Clin Oncol 2020 May 20. Epub 2020 May 20.

Surgical pathology, Instituto Nacional de Cancerología, Mexico City, Mexico.

Ovarian carcinoma is highly aggressive and difficult to treat neoplasm, which is usually detected in advanced stages where most patients recur. Extensive investigation about several treatment modalities has been performed but this neoplasm has poor benefits from such treatments including targeted therapy. Recent data have begun to highlight the histological and molecular heterogeneity of these tumors defining this neoplasm, not as a single disease but a group of heterogeneous histological subtypes with important differences in terms of genetics, morphology, oncogenesis, prognosis, chemosensitivity and especially molecular characteristics that are likely to be targets of new molecules. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-31DOI Listing

Surgical resection of early stage hepatocellular carcinoma: balancing tumor biology with the host liver.

Chin Clin Oncol 2020 May 14. Epub 2020 May 14.

Department of Surgery, Division of Surgical Oncology, University of Texas Southwestern Medical Center, Dallas, TX, USA.

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related deaths worldwide. In early stage HCC, current practice guidelines recommend surgical resection with 5-year overall survival (OS) rates approaching 60%. Due to heterogeneity of the patient population and underutilization of HCC screening, in the past only 10-37% of patients were eligible for surgical resection at the time of initial HCC diagnosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-130DOI Listing

Systemic therapy for advanced hepatocellular carcinoma: targeted therapies.

Chin Clin Oncol 2020 May 14. Epub 2020 May 14.

Department of Medical Oncology, Mayo Clinic, Rochester, MN, USA.

Therapeutic options for advanced, unresectable hepatocellular carcinoma (HCC) have changed dramatically over the last 3 years. While surgical resection, orthotropic liver transplantation, and localized therapeutic options such as ablation, radiation therapy, and embolization remain therapeutics of choice in localized disease, systemic therapy is the only option in advanced, metastatic HCC. Since the United States Food and Drug Administration (US FDA) approval of sorafenib in 2008, targeted therapies such as sunitinib, tivantinib, brivanib, erlotinib, and linifanib; monoclonal antibody- bevacizumab showed no meaningful improvement in treatment of HCC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-20-117DOI Listing

Review on gall bladder myeloid sarcoma: a great masquerader.

Chin Clin Oncol 2020 Jun 20;9(2):37. Epub 2020 May 20.

Hemato-Oncology Division, Department of Internal Medicine, Saint Vincent Hospital, Worcester, MA, USA.

Pain in abdomen has wide differentials and narrowing down the clinical possibilities depends on type of pain, location, characterization which is usually assisted by imaging studies. Cholecystitis and cholelithiasis are amongst the common causes of acute abdomen. This study reviews the literature for the clinical characteristics, differential diagnosis, treatment and prognosis of reported cases of gallbladder myeloid sarcoma (GB-MS) who presented with abdominal symptoms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco-19-250DOI Listing

Focused issue "Neoadjuvant/adjuvant treatment for early breast cancer".

Chin Clin Oncol 2020 Jun 15;9(2):26. Epub 2020 May 15.

Breast Surgical Oncology, The Cancer Institute Hospital of JFCR Tokyo,

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.09DOI Listing

Global burden of childhood and adolescent cancer.

Chin Clin Oncol 2020 Apr 28. Epub 2020 Apr 28.

Manchester Centre for Genomic Medicine, Manchester University Hospitals NHS Foundation Trust, Manchester, UK; Division of Evolution and Genomic Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.04.03DOI Listing

Central nervous system cancers in the Middle East and North Africa (MENA) region: where does Lebanon stand.

Chin Clin Oncol 2020 Jun 23;9(2):36. Epub 2020 Apr 23.

Department of Neurology, Henri-Mondor Hospital, UPEC, Assistance Publique-Hopitaux de Paris, Creteil, France.

Background: Central nervous system (CNS) cancers are rare but deadly, with little data in the literature to describe its incidence in Middle East and North Africa (MENA) region. This study investigates the incidence-rates of these cancers MENA, determine Lebanon's current state in contrast, compare the incidence-rates of these cancers in Lebanon to other countries from several regions of the world, and discuss contributing risk factors.

Methods: CNS cancers data for the years 2005 to 2015 was collected from the National Cancer Registry of Lebanon and stratified by gender and age group. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.04.02DOI Listing

Anti-angiogenic therapies in the management of glioblastoma.

Chin Clin Oncol 2020 Apr 21. Epub 2020 Apr 21.

Department of Neurological Surgery, Department of Neurology, University of California, San Francisco, CA, USA.

Angiogenesis is a central feature of glioblastoma (GBM), with contribution from several mechanisms and signaling pathways to produce an irregular, poorly constructed, and poorly connected tumor vasculature. Targeting angiogenesis has been efficacious for disease control in other cancers, and given the (I) highly vascularized environment in GBM and (II) correlation between glioma grade and prognosis, angiogenesis became a prime target of therapy in GBM as well. Here, we discuss the therapies developed to target these pathways including vascular endothelial growth factor (VEGF) signaling, mechanisms of tumor resistance to these drugs in the context of disease progression, and the evolving role of anti-angiogenic therapy in GBM. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.06DOI Listing

Target treatment with stereotactic radiation for recurrent gliomas.

Chin Clin Oncol 2020 Apr 28. Epub 2020 Apr 28.

Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

High grade gliomas (HGG) have a propensity to recur locally and have poor outcomes. As such, safe and effective treatment is paramount. Target treatment with stereotactic radiation allows safe re-irradiation through minimizing normal brain tissue radiation due to its high precision. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.05DOI Listing

Efficacy of cyclophosphamide, doxorubicin, and cisplatin for adenoid cystic carcinoma, and their relationship with the pre-chemotherapy tumor growth rate.

Chin Clin Oncol 2020 Apr;9(2):15

Department of Internal Medicine, Seoul Na'tional University Hospital, Seoul, Korea; Cancer Research Institute, Seoul National University College of Medicine, Seoul, Korea.

Background: While surgical resection is the treatment of choice for adenoid cystic carcinoma (ACC), patients with metastasis and those who cannot undergo surgery receive palliative chemotherapy. However, the role of palliative chemotherapy is not clear yet. This study aimed to evaluate the efficacy of chemotherapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) for patients with ACC; and to analyze the relationship between the pre-chemotherapy tumor growth rate (P-TGR) and treatment outcomes in patients with the recurred metastatic unresectable ACC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.07DOI Listing

Prospect of immunotherapy in neoadjuvant/adjuvant treatment for early breast cancer.

Chin Clin Oncol 2020 Jun 17;9(2):28. Epub 2020 Apr 17.

Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.

Immunotherapy is revolutionary and changing the cancer therapy of multiple solid tumors. Immunotherapy began with discovering the proteins of immune checkpoints such as programmed death-1 (PD-1), programmed death ligand-1 (PD-L1) and cytotoxic T-lymphocyte associated antigen-4 (CTLA-4). Breast cancer, unlike cancers with high tumor mutation burden, is generally considered to be of intermediate immunogenicity; therefore, the efficacy of checkpoint monotherapy is limited. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.04.01DOI Listing

Successful stereotactic radiotherapy of meningiomas in a patient with Cowden syndrome: a case report.

Chin Clin Oncol 2020 Jun 24;9(2):38. Epub 2020 Apr 24.

Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA, USA.

Cowden's Syndrome (CS) is a rare disease with increased risk for several carcinomas. Experimental studies and limited case reports have described the negative effects of radiotherapy. A 35-yearold woman presented with newly diagnosed CS and multiple meningiomas. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.04DOI Listing

A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.

Chin Clin Oncol 2020 Apr 7;9(2):16. Epub 2020 Apr 7.

Department of Radiotherapy, The First Affiliated Hospital of Nanjing Medical College, Nanjing 210029, China.

Objective: Immune checkpoint inhibitor (ICI)-associated myocarditis is a rare and potentially fatal immune-related adverse event (irAE). The study aimed to observe the occurrence of myocarditis caused by ICIs.

Methods: The clinical manifestations, diagnosis, and treatment of immune myocarditis were explored through retrospective analysis of the detailed data of typical ICI-associated myocarditis from our center and a literature review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.08DOI Listing

Neoadjuvant endocrine therapy for estrogen receptor-positive primary breast cancer.

Chin Clin Oncol 2020 Jun 31;9(2):30. Epub 2020 Mar 31.

Department of Breast and Endocrine Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan.

Neoadjuvant endocrine treatment (NAE) for estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer improves the surgical outcome, and its therapeutic response is useful for predicting prognosis. The indication for NAE is patients who have highly hormone-sensitive breast cancer. The optimal treatment duration depends on the required endpoint. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.02DOI Listing

Prediction of Immune checkpoint inhibitors benefit from routinely measurable peripheral blood parameters.

Chin Clin Oncol 2020 Apr 1;9(2):19. Epub 2020 Apr 1.

Algoma District Cancer Program, Sault Area Hospital, Sault Ste. Marie, Ontario, Canada; Section of Internal Medicine, Division of Clinical Sciences, Northern Ontario School of Medicine, Sudbury, Ontario, Canada.

Immunotherapy of cancer has been the most remarkable advance in cancer therapy in the last several years with the successful introduction of monoclonal antibody drugs that block inhibitory immune receptors to invigorate immune attack against tumors. With the introduction of these drugs the parallel need of predictive markers of response has arisen. Beyond markers from the tumor and the tumor micro-environment, the peripheral blood supplies several biomarkers for response that have been reported individually or in combinations to provide valuable predictive information. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.03DOI Listing

A view of the epidemiologic landscape: how population-based studies can lend novel insights regarding the pathophysiology of glioblastoma.

Chin Clin Oncol 2020 04 8. Epub 2020 Apr 8.

Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.

Glioblastoma is an aggressive disease that is difficult to treat, in large part due to the high level of molecular heterogeneity that limits the utility of targeted therapies. As such, population studies have been essential in characterizing the factors that promote survival. In this review, we summarize the findings in these studies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.07DOI Listing

A colonic metastasis from extrahepatic cholangiocarcinoma after removal of primary tumor: a case report and literature review.

Chin Clin Oncol 2020 Apr 1;9(2):21. Epub 2020 Apr 1.

Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China; Department of Oncology, Pukou Branch Hospital of Jiangsu Province Hospital (Nanjing Pukou Central Hospital), Nanjing 211800, China.

Metastatic cholangiocarcinoma (CCA) to the gastrointestinal tracts has rarely been described in the literature. We report a 54-year-old male patient with radical resection of an extrahepatic CCA who underwent uncommon metastatic pattern. After a recurrence-free period of 2 years, an elevated CA19- 9 initiated a CT scan, showing a tumor at the junction of rectum and sigmoid with enlarged lymph nodes around colon, mimicking a primary colon cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.08DOI Listing

Long term control stereotactic body radiotherapy (SBRT) for oligometastatic colorectal cancer: a single center study.

Chin Clin Oncol 2020 Apr 17;9(2):13. Epub 2020 Mar 17.

Medical Oncology Department, General University Hospital, Valencia, Spain.

Background: To evaluate survival after stereotactic body radiotherapy (SBRT) as radical treatment for metastases of colorectal cancer (CRC) and to identify prognostic factors after treatment.

Methods: Patients with metastatic CRC treated with SBRT on metastatic lesions were retrospectively analyzed between February 2012 and August 2016 at the General University Hospital of Valencia. The follow-up was carried out until July 15, 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.10DOI Listing

Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer.

Chin Clin Oncol 2020 Jun 13;9(2):27. Epub 2020 Mar 13.

Department of Breast Oncology, Miyake Ofuku Clinic, Okayama, Japan.

The improvement of tumor biomarkers prepared for clinical use is a long process. A good biomarker should predict not only prognosis but also the response to therapies. In this review, we describe the biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer, considering different breast cancer subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.06DOI Listing

Analysis of the association between adverse events and outcome in patients receiving a programmed death protein-1 or programmed death ligand-1 antibody.

Chin Clin Oncol 2020 Mar 4. Epub 2020 Mar 4.

Research Unit, Hospital Costa del Sol, Marbella, Málaga, Spain; Red de Investigación en Servicios de Salud en Enfermedades Crónicas (REDISSEC), ISCIII, Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain; Surgery, Biochemistry and Immunology Department, School of Medicine, University of Málaga, Málaga, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.03.01DOI Listing

Multidisciplinary sarcoma tumor board: retroperitoneal liposarcoma.

Chin Clin Oncol 2020 Apr 9;9(2):20. Epub 2020 Mar 9.

Departments of Surgery, Radiology, and Pathology, Peking University International Hospital (PKUIH), Beijing 102206, China; Beijing Spanal Medical Scientific Co. Ltd., Beijing 102206, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.08DOI Listing

Tumor treating fields in neuro-oncology: integration of alternating electric fields therapy into promising treatment strategies.

Chin Clin Oncol 2020 Feb 29. Epub 2020 Feb 29.

Brain Tumor Center & Neuro-Oncology Unit, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA.

As the most recent innovation in cancer therapy that utilizes properties of the electromagnetic spectrum, tumor treating fields (TTFields) are non-invasive alternating electrical fields that target rapidly dividing tumor cells. In the patient, TTFields are delivered as regional treatment via two pairs of orthogonally positioned transducer arrays applied to the head or elsewhere on the body surface. Side effects are primarily localized to the skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.04DOI Listing
February 2020

REACH-2: first biomarker-based anti-angiogenic therapy in patients with advanced hepatocellular carcinoma.

Chin Clin Oncol 2020 Feb 25. Epub 2020 Feb 25.

Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea; Laboratory of Translational ImmunoOncology, CHA University, Seongnam, Republic of Korea. or

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.04DOI Listing
February 2020

Are short magnetic resonance imaging protocols the future of prostate imaging?

Chin Clin Oncol 2020 Jun 25;9(2):41. Epub 2020 Feb 25.

Department of Advanced Biomedical Sciences, University "Federico II" Napoli, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2019.12.13DOI Listing

Guidelines for biliary stents and drains.

Chin Clin Oncol 2020 Feb;9(1)

The Bili Project Foundation, Pleasanton, CA, USA.

Hepatobiliary and pancreatic cancers can cause malignant biliary constriction of the bile ducts, a lethal complication that leads to obstruction of the bile ducts, cholangitis, sepsis, and death. Patients may present with symptoms such as painless jaundice, dark or amber urine, light colored stools, and weight loss. These patients often have locally advanced disease at presentation, and surgical intervention is often not possible. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.01DOI Listing
February 2020

Targets for therapy in biliary tract cancers: the new horizon of personalized medicine.

Chin Clin Oncol 2020 Feb;9(1)

Fox Chase Cancer Center, Temple University Health System, Philadelphia, PA, USA.

Biliary tract cancers (BTCs) are a set of molecularly distinct and heterogeneous diseases. While cytotoxic chemotherapy remains the current standard of care for treatment-naïve and treatment-refractory unresectable disease, recently identified mutations driving oncologic development offer opportunities for targeted therapy. Currently, alterations in the fibroblast growth factor receptor (FGFR), isocitrate dehydrogenase (IDH), v-Raf murine sarcoma viral oncogene homolog B (BRAF), DNA damage repair, and HER2 pathways have demonstrated promising new therapeutic avenues, among others, and various studies have demonstrated clinical activity with targeted tyrosine kinase inhibitors and/or antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2019.12.11DOI Listing
February 2020

On the cusp of a sea change in biliary tract cancer.

Authors:
Milind Javle

Chin Clin Oncol 2020 Feb 11;9(1). Epub 2020 Feb 11.

Professor, Gastrointestinal Oncology, UT-MD Anderson Cancer Center, Houston, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.03DOI Listing
February 2020

Biliary tract cancer and genomic alterations in homologous recombinant deficiency: exploiting synthetic lethality with PARP inhibitors.

Chin Clin Oncol 2020 Feb 20;9(1). Epub 2020 Feb 20.

Mayo Clinic, Phoenix, AZ, USA.

Biliary tract cancers (BTC) are a group of rare, chemoresistant solid tumor malignancies that arise from the bile ducts. BTC are typically associated with poor outcomes. Most patients present with advanced disease, where treatment is palliative with platinum based cytotoxic therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.02DOI Listing
February 2020

Management of glioblastoma: a perspective from Nigeria.

Chin Clin Oncol 2020 Feb 20. Epub 2020 Feb 20.

Department of Neurosurgery, University College Hospital, Ibadan, Nigeria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.06DOI Listing
February 2020

Management of glioblastoma: an Australian perspective.

Chin Clin Oncol 2020 Feb 20. Epub 2020 Feb 20.

NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; The Preston Robert Tisch Brain Tumor Center and Duke Center for Cancer Immunotherapy, Duke University, Durham, NC, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.02.05DOI Listing
February 2020

Effects of a metallic implant on radiotherapy planning treatment-experience on a human cadaver.

Chin Clin Oncol 2020 Apr 11;9(2):14. Epub 2020 Feb 11.

Department of Radiotherapy, ICANS, Institut Cancérologie Strasbourg Europe, 67200 Strasbourg Cedex, France; Strasbourg University, CNRS, IPHC UMR 7178, Centre Paul Strauss, UNICANCER, 67000 Strasbourg, France.

Background: Metallic implants (MIs) complicate radiotherapy planning. Several studies have worked on tissue-equivalent phantoms as experimental models to estimate dose distributions in this context. The application of these results to clinical practice remains disputable because the inhomogeneity of human tissue densities is a difficult factor to integrate into dose calculation software. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.09DOI Listing

PD-L1 expression and efficacy of pembrolizumab as monotherapy in NSCLC.

Chin Clin Oncol 2020 Feb 11. Epub 2020 Feb 11.

Medical Sciences, Dx-Rx Institute, Fredensborg, Denmark.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.03DOI Listing
February 2020

Indolent non-Hodgkin lymphoma treatment in the new drugs era.

Chin Clin Oncol 2020 Feb 11. Epub 2020 Feb 11.

Hematology/Oncology, Mercy Clinic Oncology and Hematology-Joplin, Joplin, MO, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.01DOI Listing
February 2020

State of art and advances on the treatment of bone metastases from breast cancer: a concise review.

Chin Clin Oncol 2020 Apr 4;9(2):18. Epub 2020 Feb 4.

Institute of Oncology of Southern Switzerland (IOSI), Bellinzona, Switzerland.

Bone is one of the most common metastatic sites in metastatic breast cancer (mBC). The presence of bone metastases can lead to various complications including pain, spinal cord compression, hypercalcaemia, pathological fractures. The treatment of bone metastases of breast cancer (BC) is mainly based on the biological characteristics of the primary tumour, but there are also specific treatments for bone lesions including bone modifiers, radionuclides, or localized treatments such as radiotherapy, surgery or vertebroplasty. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/cco.2020.01.07DOI Listing